These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37587493)

  • 21. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Mease PJ; Rahman P; Gottlieb AB; Kollmeier AP; Hsia EC; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; van der Heijde D; McInnes IB;
    Lancet; 2020 Apr; 395(10230):1126-1136. PubMed ID: 32178766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Peterson S; Agarwal P; Yang F; Kollmeier AP; Hsia EC; Shiff NJ; Zhou B; Han C; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4613-4631. PubMed ID: 35947349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR; McInnes IB; Rahman P; Gladman DD; Yang F; Peterson S; Agarwal P; Kollmeier AP; Hsia EC; Han C; Shiff NJ; Shawi M; Tillett W; Mease PJ
    Adv Ther; 2022 Oct; 39(10):4632-4644. PubMed ID: 35947348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.
    Helliwell PS; Deodhar A; Gottlieb AB; Boehncke WH; Xu XL; Xu S; Wang Y; Hsia EC; Gladman DD; Ritchlin CT
    Arthritis Care Res (Hoboken); 2020 Nov; 72(11):1579-1588. PubMed ID: 31421033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study.
    Coates LC; Gossec L; Zimmermann M; Shawi M; Rampakakis E; Shiff NJ; Kollmeier AP; Xu XL; Nash P; Mease PJ; Helliwell PS
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38531621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
    Gottlieb AB; McInnes IB; Rahman P; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; Lavie F; Mease PJ
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36828643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors.
    Kirkham B; Sesin C; Gellett AM; Sprabery AT; Lin CY; Turkiewicz A
    Rheumatology (Oxford); 2021 Sep; 60(9):4367-4372. PubMed ID: 33479721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
    J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
    Rahman P; Boehncke WH; Mease PJ; Gottlieb AB; McInnes IB; Shawi M; Wang Y; Sheng S; Kollmeier AP; Theander E; Yu J; Leibowitz E; Marrache AM; Coates LC
    J Rheumatol; 2023 Jun; 50(6):769-780. PubMed ID: 36642439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.
    FitzGerald O; Gladman DD; Mease PJ; Ritchlin C; Smolen JS; Gao L; Hu Y; Nowak M; Banerjee S; Catlett I
    Arthritis Rheumatol; 2024 Sep; 76(9):1397-1407. PubMed ID: 38770592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
    Rahman P; Ritchlin CT; Helliwell PS; Boehncke WH; Mease PJ; Gottlieb AB; Kafka S; Kollmeier AP; Hsia EC; Xu XL; Shawi M; Sheng S; Agarwal P; Zhou B; Ramachandran P; Zhuang Y; McInnes IB
    J Rheumatol; 2021 Dec; 48(12):1815-1823. PubMed ID: 33934076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials.
    Mease P; Korotaeva T; Shesternya P; Kokhan M; Rukavitsyn A; Vasilchenkov D; Sharaf M; Lavie F; Deodhar A
    Rheumatol Ther; 2024 Dec; 11(6):1551-1567. PubMed ID: 39320583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.
    Eyerich K; Asadullah K; Pinter A; Weisenseel P; Reich K; Paul C; Sabat R; Wolk K; Eyerich S; Lauffer F; Angsana J; Taut FJH; Kohler K; Chen Y; Sendecki J; Leung MWL; Wegner S; Personke Y; Gomez M; Krüger N; Tabori S; Schäkel K
    JAMA Dermatol; 2024 Sep; 160(9):953-963. PubMed ID: 39083288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies.
    Orbai AM; Husni ME; Gladman DD; Leung YY; Siebert S; Tillett W; Vis M; Chambenoit O; Meng X; Mease PJ
    Rheumatol Ther; 2021 Sep; 8(3):1223-1240. PubMed ID: 34218429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B; Coates LC; Lebwohl MG; Deodhar A; Leibowitz E; Rowland K; Kollmeier AP; Miller M; Wang Y; Li S; Chakravarty SD; Chan D; Shawi M; Yang YW; Thaҫi D; Rahman P
    Drug Saf; 2024 Jan; 47(1):39-57. PubMed ID: 37906417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.